Companies to Watch – Elegen In the last of four features on Elegen, we present a case study of how Elegen’s cell-free ENFINIA™ DNA accelerates projects with high sequence complexity from the drawing board to the incubator, saving weeks to advance research goals faster. Download the case study here This is […]
companies
Elegen’s Cell-Free DNA Synthesis Speeds the Discovery and Development of Genetic Medicines
/ big4bio
Company to Watch – Elegen In the third of four features on Elegen, Marc Unger, Chief Scientific Officer, talks about Elegen’s cell-free DNA synthesis technology ENFINIA DNA, how it changes the paradigm of discovery and development for genetic medicines, and the company’s recent collaboration with GSK. In the final feature, Elegen will present a case […]
Podcast: Solving Major Bottlenecks in Genetic Medicine and SynBio With DNA Synthesis Innovation
/ big4bio
Company to Watch – Elegen The Big4Bio Podcast · Addressing the Bottleneck in DNA Synthesis As part of April 2024’s Company to Watch program, we speak to Matt Hill, founder and CEO of Elegen, about Elegen’s ENFINIA DNA technology, the need it addresses, and how it has disrupted the status quo for DNA synthesis. […]
The Big4Bio Company to Watch Program
April 2024: Elegen
April 2024: Elegen
/ big4bio
THE COMPANY/THE MISSION Removing Bottlenecks in Synthetic Biology With Cell-Free Synthesis of Long and Complex DNA Elegen’s mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA THE TECHNOLOGY, PART 1 Podcast: Solving Major Bottlenecks in Genetic Medicine and SynBio With DNA […]
Removing Bottlenecks in Synthetic Biology with Cell-Free Synthesis of Long and Complex DNA
/ big4bio
Companies to Watch – Elegen In the first of four features on Elegen, Randy Dyer, vice president of marketing, talks about the spark behind the formation of the company as well as its mission to unlock the promise of synthetic biology by eliminating a critical bottleneck in the supply of synthetic DNA for genetic medicine […]
Unlocking the Power of RNA, Part 2
/ big4bio
In the second feature on CircNova, CSO Joe DeAngelo explains the science behind the company and why he thinks their technology can unlock the power of RNA to drug targets that have previously been undruggable. Companies to Watch – CircNova by Marie Daghlian CircNova believes circular RNA has great potential benefit for therapeutic development by […]
The Big4Bio Company to Watch Program
September 2023: CircNova
September 2023: CircNova
/ big4bio
THE COMPANY/THE MISSION Unlocking the Power of RNA, Part 1 CircNova aims to leverage AI to generate, analyze, and identify non-coding circular RNA for therapeutic development Unlocking the Power of RNA, Part 2 CSO Joe DeAngelo explains the science behind the company and why he thinks their technology can unlock the […]
Unlocking the Power of RNA, Part 1
/ big4bio
In the first of two features on CircNova, CEO Crystal Brown and CSO Joe DeAngelo recount the spark behind the formation of the company and its mission to enable the development of therapeutics for major unmet clinical needs. The second feature will discuss thinking behind CircNova’s technology. Companies to Watch – CircNova by Marie Daghlian […]
The Big4Bio Company to Watch Program
June 2023: Startup Stadium Finalists at BIO 2023
June 2023: Startup Stadium Finalists at BIO 2023
/ big4bio
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2023 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions […]
A World-Renowned Immunologist on the Promise and Passion of Senda Biosciences
/ big4bio
In the final feature explaining why Senda Biosciences is a Company to Watch, Big4Bio editor Marie Daghlian spoke with Senda Chief Scientific Officer Luke O’Neill about why he joined the company, why he is excited to be a member of Senda’s team, and what we might expect from them in the near future. Companies to […]
Podcast: Pioneering Fully Programmable Medicines
/ big4bio
In the third of four features on Senda Biosciences, we spoke to Senda CEO Guillaume Pfefer and Senda Chief Platform Officer Stuart Milstein, about its platform technology, how it is building an atlas of natural nanoparticles, and how its work is leading to a pipeline of programmable medicines. Companies to Watch – Senda Biosciences The Big4Bio […]
Medicines with Unlimited Possibility
/ big4bio
The second of four features on Senda Biosciences, based on Big4Bio’s interview with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein, focuses on the company’s technology platform – designed to harness nature’s codes to program molecules within and to the cell – and its potential to treat a broad range of diseases. Companies to […]
The Big4Bio Company to Watch Program
April 2023: Senda Biosciences
April 2023: Senda Biosciences
/ big4bio
THE COMPANY/THE MISSION Programming Medicine to Send the Right Information to the Right Cell Senda Biosciences is on a mission to harness powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. THE TECHNOLOGY, PART 1 Medicines with Unlimited Possibility Discussing the company’s technology […]
Programming Medicine to Send the Right Information to the Right Cell
/ big4bio
In the first of four features on Senda Biosciences, Big4Bio spoke with CEO Guillaume Pfefer and Chief Platform Officer Stuart Milstein about how and why the company was founded, and how molecular connections among different kingdoms of life that have co-evolved over millennia may hold the key to addressing the challenges of delivering nucleic acid […]
The Big4Bio Company to Watch Program
September 2022: Life Science Cares
September 2022: Life Science Cares
/ big4bio
Life Science Cares leverages the power of the life science industry to solve one of our most intractable social issues—poverty. They currently operate in locations that boast a critical mass of companies working in biotech, pharmaceuticals, medical technology, and research: Boston, Philadelphia, San Diego and the San Francisco Bay Area — the Big4Bio regions. Life […]